Global survival and biochemical relapse-free survival in patients with prostate cancer treated with intensity modulated radiotherapy (IMRT) at the National Cancer Institute.

Revista Colombiana de Cancerología

View Publication Info
 
 
Field Value
 
Title Global survival and biochemical relapse-free survival in patients with prostate cancer treated with intensity modulated radiotherapy (IMRT) at the National Cancer Institute.
Supervivencia global y supervivencia libre de recaída bioquímica en pacientes con cáncer de próstata tratados con radioterapia de intensidad modulada (IMRT) en el Instituto Nacional de Cancerología
 
Creator Jimenez Cotes, Adriana
Esguerra Cantillo, Jose Alejandro
Ospino Peña, Rosalba
Morales Ramirez, Laura
Noreña Gomez, Maria Paulina
Ballesteros, Holman
Gonzalez, Garvin
Rugeles, Jorge
 
Subject Prostatic Neoplasms
Radiotherapy
Intensity-Modulated Radiation Therapy
Neoplasias de la próstata
Radioterapia
Radioterapia de intensidad modulada
 
Description Abstract
Background: In 2018, prostate cancer ranked second in incidence worldwide. Advances in technology and the appearance of intensity-modulated radiotherapy, have made it possible to reduce doses to healthy tissue without reducing the coverage of the target volume, thus allowing lower morbidity associated with radiotherapy and the possibility of scaling the treatment dose. The aim of the study was to present the results in overall survival and biochemical relapse-free survival at the Colombian National Cancer Institute (INC) in patients diagnosed with non-metastatic prostate cancer treated with intensity-modulated radiotherapy (IMRT).
Material and methods: The retrospective review included 98 patients over 40 years of age with prostate cancer, without evidence of metastatic disease, treated with IMRT between 2008 and 2015 irrespective of androgenic suppression. The administered dose of radiotherapy varied according to their risk based on the D'Amico classification.Results: The median age was 68.5 years, and of the total of 98 patients, 16 (16%) were classified as low risk, 33 (33%) as intermediate risk, and 49 (50%) as high risk. The mean dose of radiation therapy received was 75.8 Gy. Biochemical relapse-free survival at 5 years was 78.6%, and overall survival was 98%.
Conclusions:  In patients with high-risk prostate cancer, IMRT is an effective and safe alternative, with an overall 5-year survival of 98%, and an adequate dosimetric profile for at-risk organs.
Introducción: En el 2018 el cáncer de próstata presentó el segundo lugar en incidencia a nivel mundial (1). Con el avance en la tecnología y la aparición de la radioterapia de intensidad modulada (IMRT), se ha logrado disminuir dosis a tejido sano sin reducir la cobertura del volumen objetivo, permitiendo menor morbilidad asociada por la radioterapia y la posibilidad de escalar la dosis del tratamiento. El objetivo del estudio fue mostrar los resultados en supervivencia global y supervivencia libre de recaída bioquímica en el Instituto Nacional de Cancerología (INC) en los paciente diagnosticados con cáncer de próstata tratados con radioterapia de intensidad modulada (IMRT).
Materiales y métodos: la revisión retrospectiva incluyó 98 pacientes, mayores de 40 años con cáncer de próstata, sin evidencia de enfermedad metastásica, tratados con IMRT entre 2008 - 2015, independiente de la supresión androgénica. La dosis administrada de radioterapia varió según su riesgo basado en la clasificación D´Amico.
Hallazgos: La mediana de edad fue de 68,5 años, dentro de los cuales 16 pacientes (16%) se catalogaron de bajo riesgo, 33 (34%) de riesgo intermedio y 49 (50 %) de riesgo alto. La dosis media de radioterapia recibida fue de 75,8 Gy. La supervivencia libre de recaída bioquímica a 5 años fue del 78,6 % y la supervivencia global fue 98 %.
Conclusión: Se obtuvo una supervivencia global y una supervivencia libre de recaída bioquímica a 5 años del 98% y 73,1% respectivamente.
 
Publisher Instituto Nacional de Cancerología
 
Date 2020-11-30
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://www.revistacancercol.org/index.php/cancer/article/view/6
10.35509/01239015.6
 
Source Revista Colombiana de Cancerología; Vol. 24 No. 4 (2020); 157-63
Revista Colombiana de Cancerología; Vol. 24 Núm. 4 (2020); 157-63
Revista Colombiana de Cancerología; v. 24 n. 4 (2020); 157-63
2346-0199
0123-9015
 
Language spa
 
Relation https://www.revistacancercol.org/index.php/cancer/article/view/6/517
/*ref*/Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England). 2018;391(10125):1023-75. https://doi.org/10.1016/S0140-6736(17)33326-3 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 3. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama. 2005;294(10):1233-9. https://doi.org/10.1001/jama.294.10.1233 4. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International journal of radiation oncology, biology, physics. 2008;70(1):67-74. https://doi.org/10.1016/j.ijrobp.2007.06.054 5. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(13):1990-6. https://doi.org/10.1200/JCO.2005.05.2530 6. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. The Journal of urology. 2001;166(3):876-81. https://doi.org/10.1016/S0022-5347(05)65855-7 7. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Sturmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. Jama. 2012;307(15):1611-20. https://doi.org/10.1001/jama.2012.460 8. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International journal of radiation oncology, biology, physics. 2008;70(4):1124-9. https://doi.org/10.1016/j.ijrobp.2007.11.044 9. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)). 2010;22(8):643-57. https://doi.org/10.1016/j.clon.2010.06.013 10. Pardo C, de Vries E, Acero D, Murillo R. Vigilancia de la supervivencia global por cáncer en Colombia: utilidad de los registros rutinarios. Revista Colombiana de Cancerología. 2015;19(2):81-9. https://doi.org/10.1016/j.rccan.2015.03.001 11. Pardo C, de Vries E. Supervivencia global de pacientes con cáncer en el Instituto Nacional de Cancerología (INC). Revista Colombiana de Cancerología. 2017;21(1):12-8. https://doi.org/10.1016/j.rccan.2017.01.003 12. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. International journal of radiation oncology, biology, physics. 2007;68(5):1424-30. https://doi.org/10.1016/j.ijrobp.2007.01.067 13. Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. The Journal of urology. 2013;190(2):521-6. https://doi.org/10.1016/j.juro.2013.02.012
 
Rights Derechos de autor 2020 Revista Colombiana de Cancerología
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library